Medicine and Dentistry
Health Care Cost
68%
Maturity Onset Diabetes of the Young
59%
Chronic Kidney Disease
58%
Cost-Effectiveness Analysis
57%
Drug Therapy
55%
Cardiovascular System
45%
Global Disease Burden
43%
Disease
41%
Diabetes
41%
Systematic Review
37%
Patient with Type 2 Diabetes
36%
Albuminuria
35%
Glomerular Filtration Rate
34%
Nephropathy
27%
Prevalence
27%
Asthma
26%
Cohort Analysis
25%
Chronic Obstructive Pulmonary Disease
25%
Canagliflozin
25%
Creatinine
25%
Placebo
25%
Clinical Trial
24%
Dapagliflozin
23%
Primary Health Care
22%
Urinary System
22%
Randomized Controlled Trial
22%
Quality of Life
21%
Sodium Glucose Cotransporter 2 Inhibitor
21%
Medicine
21%
COVID-19
21%
Meta-Analysis
20%
Diabetic Nephropathy
20%
Kidney Function
20%
Cardiovascular Disease
19%
Heart Failure
18%
Hazard Ratio
18%
Adverse Drug Reaction
17%
Post-Hoc Analysis
17%
Disability Adjusted Life Years
17%
Venous Thromboembolism
16%
Biological Marker
16%
Quality Adjusted Life Year
14%
Infection
14%
Blood Pressure
13%
Observational Study
13%
Bleeding
13%
Kidney Graft
13%
Renal Failure
12%
Diabetes Mellitus
12%
End Stage Renal Disease
12%
Vitamin K Antagonist
12%
Low and Middle Income Countries
11%
Von Willebrand Disease
11%
Malignant Neoplasm
11%
Cardiovascular Risk
11%
Medication Compliance
11%
Disease Exacerbation
11%
Hemoglobin A1c
11%
Adverse Event
11%
Odds Ratio
11%
Atrial Fibrillation
10%
Injury
10%
Health Care
10%
Mortality Rate
10%
Cross Sectional Study
9%
Haemophilia A
9%
Symptom
9%
Randomized Clinical Trial
9%
Decision Making
8%
Bleeding Disorder
8%
Outpatient
8%
Human Immunodeficiency Virus
8%
General Practitioner
8%
Apoplexy
8%
Health Technology
8%
Diagnosis
8%
Population
8%
Life Expectancy
8%
Health Outcomes
7%
Retrospective Cohort Study
7%
Patient-Reported Outcome
7%
Systolic Blood Pressure
7%
Influenza Vaccine
7%
Glycon
7%
Adverse Outcome
7%
Technology Assessment
6%
Proportional Hazards Model
6%
Antithrombotic
6%
Von Willebrand Factor
6%
Metabolic Syndrome
6%
Blood Clotting Factor 8
6%
Influenza Vaccination
6%
General Medicine
6%
Renin Angiotensin Aldosterone System
6%
Sex Difference
6%
Public Health
6%
Patient with Asthma
6%
Childbirth
6%
Intensive Care Unit
5%
Antibiotics
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Chronic Kidney Failure
59%
Disease
56%
Adverse Drug Reaction
49%
Dapagliflozin
45%
Prevalence
45%
Cohort Study
44%
Albuminuria
43%
Asthma
40%
Chronic Obstructive Lung Disease
40%
Placebo
39%
Global Disease Burden
36%
Creatinine
36%
Vaccination Policy
33%
Randomized Controlled Trial
32%
Sodium Glucose Cotransporter 2 Inhibitor
31%
Kidney Disease
30%
Clinical Trial
29%
Canagliflozin
25%
Diabetic Nephropathy
25%
Pharmacovigilance
25%
Heart Failure
23%
Adverse Event
23%
Cardiovascular Disease
22%
Pharmacokinetics
20%
Infection
20%
Venous Thromboembolism
20%
Antivitamin K
19%
Antihypertensive Agent
18%
Community Pharmacy
18%
Pharmacotherapy
18%
Malignant Neoplasm
17%
Biological Marker
17%
Bleeding
16%
Symptom
16%
Observational Study
15%
Anticoagulant Agent
15%
Cross-Sectional Study
15%
Comorbidity
15%
End Stage Renal Disease
14%
Kidney Failure
14%
Cardiovascular Risk
14%
Haemophilia A
14%
Hemoglobin A1c
13%
Statin (Protein)
13%
Antibiotics
13%
HIV
12%
Diabetes Mellitus
12%
Atrial Fibrillation
12%
Atrasentan
12%
Live Attenuated Influenza Vaccine
12%
Pharmacogenetics
11%
Blood Clotting Factor 8
11%
Drug Safety
11%
Disease Exacerbation
10%
Influenza Vaccine
10%
Case-Control Study
10%
Antipsychotic
10%
Injury
10%
Randomized Clinical Trial
9%
Von Willebrand Disease
9%
Metformin
9%
Antidepressant
9%
Drug-Drug Interaction
9%
Adverse Outcome
9%
CYP2D6
9%
Antibiotic Agent
9%
Typical Antipsychotic
9%
Cholinergic Receptor Blocking Agent
9%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Medication Error
9%
Combination Therapy
8%
Biological Product
8%
Base
8%
Side Effect
8%
Polypharmacy
8%
Angiotensin Receptor Antagonist
8%
Renin
7%
Mortality Rate
7%
Direct Oral Anticoagulant
7%
Angiotensin
7%
Ciclonicate
7%
Prospective Cohort Study
7%
Von Willebrand Factor
7%
All Cause Mortality
7%
Empagliflozin
7%
Therapeutic Drug Monitoring
6%
Low Density Lipoprotein Cholesterol
6%
Dabigatran
6%
Metabolic Syndrome X
6%
Epileptic Absence
6%
Prothrombin Complex
6%
Haemophilia
6%
Tardive Dyskinesia
6%
Thrombosis
5%
Non Communicable Disease
5%
Prospective Study
5%
Low Molecular Weight Heparin
5%
Liver Cirrhosis
5%
Hyperprolactinemia
5%
Keyphrases
Type 2 Diabetic Patients
45%
Netherlands
44%
Chronic Kidney Disease
44%
Type 2 Diabetes Mellitus (T2DM)
40%
Albuminuria
33%
Dapagliflozin
32%
Confidence Interval
32%
Dutch
25%
Cost-effectiveness
24%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
23%
Estimated Glomerular Filtration Rate
22%
Albumin-to-creatinine Ratio
22%
Canagliflozin
21%
Diabetic Kidney Disease
18%
Diabetes
17%
Placebo
16%
Cardiovascular Outcomes
16%
Adverse Drug Reaction
15%
Risk Factors
14%
Meta-analysis
14%
Hazard Ratio
13%
Medication Adherence
13%
Asthma
12%
Healthcare Professionals
12%
Comorbidity
11%
Chronic Obstructive Pulmonary Disease
11%
Randomized Controlled Trial
11%
Kidney Outcomes
11%
Patients with Diabetes
11%
Venous Thromboembolism
11%
Quality of Life
11%
Statins
10%
Von Willebrand Disease
10%
Primary Care
10%
Cost-effectiveness Analysis
10%
COVID-19
10%
Pharmacist
10%
Clinical Trials
9%
Global Burden of Disease Study
9%
Non-adherence
9%
Hemoglobin A1c (HbA1c)
9%
Cardiovascular Mortality
9%
Heart Failure
8%
Renal Outcome
8%
Hemophilia
8%
Patients with Schizophrenia
8%
Odds Ratio
8%
Health-related Quality of Life
8%
Schizophrenia
8%
Clinical Outcomes
8%
General Practitioners
8%
Medication Use
8%
Nephropathy
8%
High Risk
8%
Kidney
8%
Adverse Outcomes
8%
Kidney Transplant Recipients
7%
Vitamin K Antagonists
7%
Cardiovascular Disease
7%
Kidney Function
7%
Health Economics
7%
Atrial Fibrillation
7%
Indonesia
7%
Systematic Meta-analysis
7%
Polypharmacy
7%
Quality-adjusted Life Years
7%
Systolic Blood Pressure
7%
Psychosis
7%
Kidney Failure
7%
Risk Markers
7%
Antipsychotics
7%
Pharmacist Intervention
7%
Older Patients
6%
Kidney Disease Progression
6%
Disability-adjusted Life Years
6%
Clinical Practice
6%
Hypertension
6%
Atrasentan
6%
Groningen
6%
Metabolic Syndrome
6%
Pharmacy
6%
Antidepressants
6%
Prospective Cohort Study
6%
Economic Evaluation
6%
Statin Therapy
6%
Randomized Clinical Trial
6%
Europe
6%
Global Burden of Disease 2019
6%
Blood Pressure
6%
Antihypertensive Drugs
6%
Renal Events
6%
Hospitalization
6%
Cardiovascular Risk
6%
Drug Use
6%
Clinical Evaluation
6%
Global Burden
5%
Sex Differences
5%
Urinary Albumin Excretion
5%
Adverse Events
5%
Attention Deficit Hyperactivity Disorder
5%